COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
FDA issues COVID-19 policies on clinical trials for medical products, mammography quality standards.
The Food and Drug Administration Dec. 4 issued guidance on how to conduct clinical trials for medical products during the COVID-19 public health emergency.
The Centers for Medicare & Medicaid Services has identified the Healthcare Common Procedural Coding System codes and Medicare Part B payment allowances effective Nov. 21 for administering casirivimab and imdevimab, a combination monoclonal antibody therapy made by Regeneron.
The AHA will host two important calls for hospital and health system leaders on issues related to the COVID-19 pandemic.
The FDA this week revised and reissued its August emergency use authorization for COVID-19 convalescent plasma to treat hospitalized patients with COVID-19. The revised EUA adds the Mount Sinai COVID-19 ELISA IgG Antibody Test as an acceptable test for qualifying high and low titer COVID-19…
The Centers for Disease Control and Prevention announced shorter quarantine options based on local circumstances and resources, for people exposed to the COVID-19 virus.
An independent advisory group for the Centers for Disease Control and Prevention recommended health care personnel and long-term care facility residents receive vaccinations against COVID-19 in the program’s initial phase.
The AHA asks the Department of Health and Human Services (HHS) to take additional steps to increase flexibilities for providers responding to the COVID-19 pandemic.
A new report from the Centers for Disease Control and Prevention looks at an outbreak of Carbapenem-resistant Acinetobacter baumannii (CRAB), an antibiotic-resistant bacteria, at a New Jersey hospital managing resource shortages during a surge in COVID-19 patients.
Effective Feb. 1, physicians and other health care providers and suppliers should use new National Uniform Billing Committee condition codes on claims for COVID-19 and other treatments authorized by the Food and Drug Administration for emergency use or expanded access, the Centers for Medicare…
The Food and Drug Administration released enforcement policy guidance for health care providers and others using dry heat systems to reduce bioburden on certain N95 and other respirators in limited supply to support reuse by health care personnel during the COVID-19 public health emergency.